Short therapy program for young adults with borderline personality disorder
Short Integrative And Neurocognitive Therapy For Young Adults With Borderline Personality Disorder: a Study Model of Impulsivity Management
This study is testing a new 10-week therapy program for young adults with borderline personality disorder to see if it can help reduce impulsive behaviors and improve their overall well-being.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 74 (estimated) |
| Ages | 16 Years to 25 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nīmes Academic / other |
| Locations | 1 site (Nîmes) |
| Trial ID | NCT05913544 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of the SINTYA therapy program, which consists of one group session and one individual session per week for 10 weeks, aimed at reducing impulsivity and clinical symptoms in young adults aged 16 to 25 diagnosed with borderline personality disorder (BPD). The program is designed to address the unique neurocognitive challenges faced by this population, particularly those linked to early trauma. Participants will be assessed for various symptoms including emotional regulation difficulties, self-destructive behaviors, and overall psychosocial functioning. The study aims to provide a tailored therapeutic approach that may be more effective than traditional psychotherapies.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 16 to 25 who have a diagnosis of borderline personality disorder and meet specific severity criteria.
Not a fit: Patients with neurological disorders, low IQ, or those currently engaged in other specific psychotherapies for BPD may not benefit from this study.
Why it matters
Potential benefit: If successful, this therapy could significantly improve the quality of life and mental health outcomes for young adults with borderline personality disorder.
How similar studies have performed: While there is limited information on the success of similar integrative approaches, the tailored nature of this therapy for young adults with BPD represents a novel intervention.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale. * High BPD severity level: ZAN-BPD (score ≥ 18/36). * Understand, write and read French. * Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations. * Have signed the informed consent. * For minor patients, have signed the parental consent by at least one holder of parental authority. Exclusion Criteria: * Refusal to participate. * Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance. * Intelligence quotient \< 70. * Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7). * Previous or current participation in specific psychotherapy for BPD. * Subject deprived of liberty (by judicial or administrative decision) and/or protected by law. * Inclusion in another study including psychotherapy for the duration of the study. * Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study. * Subject in period of exclusion from another research protocol.
Where this trial is running
Nîmes
- CHU de Nîmes — Nîmes, France (Recruiting)
Study contacts
- Principal investigator: Clémentine Estric — CHU de Nimes
- Study coordinator: Clémentine Estric
- Email: clementine.estric@chu-nimes.fr
- Phone: 04 66 68 34 26
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.